ABEONA THERAPEUTICS INC.
ABEO evidence brief
What we can confirm
- BioSniper Score:
- 6.3 / 10
- Market Cap:
- $309.7M
- Lead Asset:
- aav204 (Preclinical)
What it means
What to watch
Prepared research question
What matters most for ABEO—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ABEO
ABEONA THERAPEUTICS INC. is a commercial-stage biopharmaceutical company developing cell and gene therapies, with its first FDA-approved product ZEVASKYN for recessive dystrophic epidermolysis bullosa (RDEB) generating early revenue.
Key risk: Ongoing operating losses
BioSniper Score
Based on 4 of 6 signals
Market Cap
$309.7M
Cash Runway
—
Lead Asset
aav204 (Preclinical)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 3 pipeline candidates · 3 clinical trials for ABEONA THERAPEUTICS INC..
ABEONA THERAPEUTICS INC. is a commercial-stage biopharmaceutical company developing cell and gene therapies, with its first FDA-approved product ZEVASKYN for recessive dystrophic epidermolysis bullosa (RDEB) generating early revenue.
- FDA approved ZEVASKYN (prademagene zamikeracel) on April 28, 2025 for RDEB [sec_mda · as of 2026-03-17]
- Q2 2026 net ZEVASKYN revenue was $11.4 million, up 31% quarter-over-quarter [news · published 2026-08-13]
- Cash, cash equivalents and short-term investments totaled $146.8 million as of June 30, 2026 [news · published 2026-08-13]
- Net income was -$20.2M for the period ending June 30, 2026 [latest reported financials as of 2026-06-30]
- Pipeline includes ABO-701, a T-cell therapy targeting PSMA for prostate cancer [sec_mda · as of 2026-05-13]
What works
- ZEVASKYN is the first FDA-approved gene therapy for RDEB, with orphan drug, RPD, RMAT, and breakthrough therapy designations [pipeline]
- Revenue from ZEVASKYN is growing, with Q2 2026 net revenue of $11.4 million and 12 total treatments completed since launch [news · published 2026-08-13]
- The qualified treatment center network expanded to seven sites nationwide, increasing patient access [news · published 2026-08-13]
- Cash position is strong at $146.8 million as of June 30, 2026, providing runway for commercialization and development [news · published 2026-08-13]
What to weigh
- The company has not been profitable since inception and expects continued operating losses and negative cash flows [sec_mda · as of 2026-08-13]
- Net income was -$20.2M for the period ending June 30, 2026, indicating ongoing losses [latest reported financials as of 2026-06-30]
- Future capital needs depend on successful commercialization of ZEVASKYN and development of other candidates, with risk of needing to delay or terminate programs if funding is insufficient [sec_mda · as of 2026-08-13]
- ABO-701 is still in preclinical development, with no guarantee of successful advancement or regulatory acceptance [sec · filed 2026-06-04]
From the filings
Quoted directly from source documents.
FDA approval of ZEVASKYN
“On April 28, 2025, the FDA approved ZEVASKYN ® (prademagene zamikeracel) gene-modifi”
SEC MD&A · March 17, 2026
Q2 2026 ZEVASKYN revenue and growth
“Q2 net ZEVASKYN® revenue increased 31% quarter-over-quarter to $11.4 million”
News · August 13, 2026
Cash position as of June 30, 2026
“$146.8 million in cash, cash equivalents and short-term investments as of June 30, 2026”
News · August 13, 2026
Company has not been profitable since inception
“we have not been profitable since inception and to date have received limited revenues from the sale of products or licenses”
SEC MD&A · August 13, 2026
Risks & what to watch (4)›
Key risks
- Ongoing operating losses — Net income -$20.2M as of 2026-06-30; company has not been profitable since inception [latest reported financials as of 2026-06-30]
- Dependence on ZEVASKYN revenue — Future capital adequacy depends on successful commercialization of ZEVASKYN; limited revenue to date [sec_mda · as of 2026-08-13]
- Preclinical stage of ABO-701 — ABO-701 is in preclinical development; IND submission timing and regulatory acceptance are uncertain [sec · filed 2026-06-04]
- Need for additional financing — If unable to raise funds, may need to delay or terminate programs or grant unfavorable rights [sec_mda · as of 2026-08-13]
What to watch
- ZEVASKYN revenue growth and number of patients treated in subsequent quarters [news · published 2026-08-13]
- Expansion of the qualified treatment center network and patient progression through treatment [news · published 2026-08-13]
- Progress of ABO-701 preclinical development and timing of IND submission [sec · filed 2026-06-04]
- Cash runway and any additional equity or debt financing activities [sec_mda · as of 2026-08-13]
Sources: News · Pipeline · SEC filings · SEC MD&A · Generated October 7, 2026 · How we verify sources →
Run ABEONA THERAPEUTICS INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available ABEONA THERAPEUTICS INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.40 · 0% dilution
Lead: Approved
3 candidates
No upcoming catalysts tracked
0 buys · 19 sells (180d)
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
107
Total value held
$176.8M
| Holder | Shares | Value |
|---|---|---|
| nantahala capital management, llc | 5,013,052 | $22.5M |
| blackrock, inc. | 3,195,530 | $14.3M |
| aigh capital management llc | 3,100,000 | $13.9M |
| cable car capital, lp | 3,007,329 | $13.5M |
| suvretta capital management, llc | 2,676,000 | $12.0M |
| vanguard capital management llc | 2,164,851 | $9.7M |
| propel bio management, llc | 1,329,899 | $6.0M |
| kennedy capital management llc | 1,263,511 | $5.7M |
| geode capital management, llc | 1,209,797 | $5.4M |
| goldman sachs group inc | 1,130,619 | $5.1M |
Showing top 10 of 107 institutional holders of ABEONA THERAPEUTICS INC.. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 31.1%
- Days to cover
- 16.9
- Shares short
- 16,486,060
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ABEO short interestGovernance
Frequently asked questions
What is the AI investment thesis for ABEONA THERAPEUTICS INC.?
ABEONA THERAPEUTICS INC. is a commercial-stage biopharmaceutical company developing cell and gene therapies, with its first FDA-approved product ZEVASKYN for recessive dystrophic epidermolysis bullosa (RDEB) generating early revenue.
What is ABEONA THERAPEUTICS INC.'s lead drug candidate?
ABEONA THERAPEUTICS INC.'s most advanced tracked candidate is aav204 (Preclinical) for Ophthalmology indications.
Who is the CEO of ABEONA THERAPEUTICS INC.?
Dr. Vishwas Seshadri M.B.A., Ph.D. is the chief executive officer of ABEONA THERAPEUTICS INC. (ABEO).
Where is ABEONA THERAPEUTICS INC. headquartered?
ABEONA THERAPEUTICS INC. (ABEO) is headquartered in Cleveland, OH, United States.
What therapeutic areas does ABEONA THERAPEUTICS INC. focus on?
ABEONA THERAPEUTICS INC. develops therapies across Ophthalmology, Dermatology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.